{"id":1347,"date":"2022-07-28T13:15:13","date_gmt":"2022-07-28T11:15:13","guid":{"rendered":"https:\/\/www.olym.nl\/?p=1347"},"modified":"2022-07-28T13:16:00","modified_gmt":"2022-07-28T11:16:00","slug":"axion-biosystems-acquires-cytosmart","status":"publish","type":"post","link":"https:\/\/www.olym.nl\/en\/2022\/1347\/","title":{"rendered":"Axion BioSystems acquires CytoSMART"},"content":{"rendered":"<p>Axion BioSystems is a US-based life sciences tools company focused on advanced live-cell assay systems and a portfolio company of Summa Equity. Axion BioSystems has acquired CytoSMART, a Dutch biotechnology company focused on kinetic live-cell imaging analysis. The acquisition of CytoSMART puts Axion in a position for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. We advised CytoSMART and its selling shareholders, including Holland Capital, BOM and ECFG (Eindhoven Corporate Finance Group), on this transaction.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Axion BioSystems is a US-based life sciences tools company focused on advanced live-cell assay systems and a portfolio company of Summa Equity. Axion BioSystems has acquired CytoSMART, a Dutch biotechnology company focused on kinetic live-cell imaging analysis. The acquisition of CytoSMART puts Axion in a position for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. We advised CytoSMART and its selling shareholders, including Holland Capital, BOM and ECFG (Eindhoven Corporate Finance Group), on this transaction.<\/p>\n","protected":false},"author":6,"featured_media":1344,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[34,30,35,36],"tags":[],"class_list":["post-1347","post","type-post","status-publish","format-standard","has-post-thumbnail","category-ma-en","category-marcel-van-de-vorst-en","category-private-equity-en","category-venture-capital-en"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts\/1347","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/comments?post=1347"}],"version-history":[{"count":1,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts\/1347\/revisions"}],"predecessor-version":[{"id":1348,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/posts\/1347\/revisions\/1348"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/media\/1344"}],"wp:attachment":[{"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/media?parent=1347"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/categories?post=1347"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.olym.nl\/en\/wp-json\/wp\/v2\/tags?post=1347"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}